INTECH Investment Management’s ADC Therapeutics ADCT Stock Holding History

INTECH Investment Management’s Portfolio ADCT Stock Details ADCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.3K	Buy	28,273 +4,285	+18%	+$12.5K	﹤0.01%	2091
2026 Q1	$90K	Sell	23,988 -12,952	-35%	-$51.1K	﹤0.01%	1912
2025 Q4	$130K	Buy	36,940 +759	+2%	+$3.08K	﹤0.01%	2102
2025 Q3	$145K	Hold	36,181	–	–	﹤0.01%	2163
2025 Q2	$97K	Sell	36,181 -26,691	-42%	-$56.1K	﹤0.01%	2302
2025 Q1	$88.7K	Buy	62,872 +24,437	+64%	+$41.5K	﹤0.01%	2344
2024 Q4	$76.5K	Buy	38,435 +25,437	+196%	+$66.6K	﹤0.01%	2265
2024 Q3	$40.9K	Buy	+12,998	New	+$41K	﹤0.01%	1997

Other funds holding ADCT

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

INTECH Investment Management's ADCT Position: Q2 2026 in Review

INTECH Investment Management increased its ADC Therapeutics (ADCT) stake by 18% in Q2 2026, buying an estimated $12.5K and bringing the position to 28,273 shares worth $30.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

INTECH Investment Management first reported a position in ADCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $145K in Q3 2025. 114 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

INTECH Investment Management held 28,273 shares of ADC Therapeutics worth $30.3K as of Q2 2026.
INTECH Investment Management bought 4,285 ADC Therapeutics shares in Q2 2026, an estimated $12.5K.
ADC Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #2091 holding.
INTECH Investment Management first reported a position in ADC Therapeutics in Q3 2024 and has held it in 8 quarters since.
INTECH Investment Management's ADC Therapeutics position peaked at $145K in Q3 2025.
114 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.